Stem cell trick may free kidney patients from daily pills
NCT ID NCT03707262
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving a kidney transplant recipient blood stem cells from their sibling donor can train the body to accept the new kidney without lifelong anti-rejection drugs. Fifteen adults receiving a kidney from an identical sibling will get a conditioning regimen of radiation and an immune-suppressing drug, followed by a stem cell infusion. The goal is to see if they can safely stop all immunosuppressive medications one year after transplant.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Donor blood stem cells and immune cells
What this could lead to
If it works, this could allow kidney transplant recipients to stop taking lifelong anti-rejection medications without losing their new kidney.
What could go wrong
This is a very early, small study (15 people) testing a complex procedure. The treatment may fail to create tolerance, and there are risks from radiation, immune suppression, and stem cell infusion.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END STAGE RENAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, Los Angeles
RECRUITINGLos Angeles, California, 90095, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••